- Pixium Vision organize an open day for investors on October 13thth 2022 out 17 o’clock
- Registration required – Limited availability
Paris, France, September21, 2022 – 07:00 CET – PixiumVision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company developing innovative bionic vision systems to help patients who have lost their sight to live more independently, today announced that on Thursday October it will host an Open -House event for investors will be held 13th2022.
The event, taking place from 17:00 to 19:00 CET, will be held in French and will feature an introduction by Lloyd Diamond, Chief Executive Officer, and Brian Burg, Director of R&D, on Pixium Vision and its forthcoming Prima System bionic vision system clinical and developmental milestones and an overview of the dry age-related macular degeneration (AMD) disease and market landscape. There will be a guided tour of the Pixium Vision labs including a technology demonstration. The event will end with a drinks reception offering the opportunity to speak directly with the Pixium Vision team and use virtual reality to better understand the Prima system.
The Prima system, which has the potential to significantly improve the lives of patients with dry AMD,
is being investigated in the pivotal PRIMAvera study, which aims to confirm its safety and benefit and is the final clinical step before filing for marketing authorization in Europe. The study was initiated in France in Q4 2020 and clinical centers have now also been established in Germany, Great Britain, the Netherlands and Italy. Patient enrollment has recently been completed, giving confidence to achieve the goal of implanting all PRIMAvera patients by the end of 2022, leading to an evaluation of the PRIMAvera study towards the end of 2023.
Participation in the event is reserved for current investors only!
Please register here for the event, which will be held at the Pixium Vision offices in Paris.
Proof of share ownership is required upon registration. Please note that the registration link will be removed once the maximum capacity is reached.
Around Pixium Vision
Pixium Vision creates a world of bionic vision for people who have lost their sight, allowing them to regain visual perception and more autonomy. Pixium Vision’s bionic vision systems involve a surgical procedure and a rehabilitation period. Prima System’s miniature subretinal photovoltaic wireless implant is in clinical trials for patients who have lost their sight due to external retinal degeneration, initially due to atrophic dry age-related macular degeneration (dry AMD). Pixium Vision works closely with academic and research partners, including some of the most prestigious vision research institutes in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona , University Hospital in Bonn and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualified as “Entreprise Innovante” by Bpifrance.
Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated. Please refer to the “Facteurs de Risques” section for a discussion of the risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements. the Corporate Report 2021 Half-Yearly Financial Report and other documents that the Company files with the AMF, which are available on the AMF website (www.amf-france.org) or on the Company’s website.
For more informations: http://www.pixium-vision.com/fr
follow us on @PixiumVision; www.facebook.com/pixiumvision
+33 1 76 21 47 68
Guillaume van Rentergem
+41 76 735 01 31